In the context of cancer, MHC Class I molecules present tumor-associated antigens (TAAs) on the surface of cancer cells. These antigens are recognized by CTLs, which can then target and destroy the cancer cells. This process is a key aspect of cancer immunosurveillance, where the immune system constantly monitors and eliminates emerging cancer cells.
